Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Ondrej FialaVeronika VeskrnovaRenata ChloupkovaAlexandr PoprachIgor KissKaterina KopeckovaLadislav DusekLubomir SlavicekMilan KohoutekJindrich FinekMarek SvobodaLubos PetruzelkaLudmila BoublikováJosef DvorakBohuslav MelicharTomas Buchler

Published in: Targeted oncology (2019)

Delayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.

Keyphrases

small cell lung cancer
metastatic colorectal cancer
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
newly diagnosed
chronic kidney disease
mesenchymal stem cells
locally advanced
rectal cancer
patient reported